Strategic Diagnostics to Supply Antibodies for SAIC, NCI Proteomic Studies | GenomeWeb
NEW YORK (GenomeWeb News) – Strategic Diagnostics said yesterday that it will provide monoclonal antibodies for a proteomic study being conducted by Science Applications International Corporation – Frederick and the National Cancer Institute.
 
SDI’s antibodies will be used as reference reagents for the Proteomics Reagents & Resources component of the National Cancer Institute’s Clinical Proteomic Technologies for Cancer initiative.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.

Research funding in Canada is to remain mostly the same, ScienceInsider reports.

In Science this week: random DNA replication errors play role in cancer, and more.

The Bill and Melinda Gates Foundation embarks on an open-access publishing path.